Home › Acute Myeloid Leukemia › Tennessee
Acute Myeloid Leukemia clinical trials in Tennessee
31 studies for Acute Myeloid Leukemia are looking for participants at sites in Tennessee.
Cities in Tennessee
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- Baptist Memorial Hospital and Cancer Center-Collierville, Collierville
- Baptist Memorial Hospital and Cancer Center-Memphis, Memphis
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06317649Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- Baptist Clinical Research Institute, Memphis
- Tennessee Oncology, Nashville
- TriStar Centennial Medical Center, Nashville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07007312Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- Baptist Memorial Hospital and Cancer Center-Collierville, Collierville
- Baptist Memorial Hospital and Cancer Center-Memphis, Memphis
RecruitingPhase 2
Ages 18 to 59 · All sexes · Updated Nov 9, 2026 · NCT05554406HPC Offered for PRESERVE Expansion
- Tristar Centennial Medical Center, Nashville
RecruitingObservational study
Ages 12 to 80 · All sexes · Updated Nov 6, 2026 · NCT07145411A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML
- Vanderbilt University Medical Center, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT07751991A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- University of Tennessee, Knoxville
- Vanderbilt Ingram Cancer Center, Nashville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT06852222MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Baptist Memorial Hospital and Cancer Center-Collierville, Collierville
- Baptist Memorial Hospital and Cancer Center-Memphis, Memphis
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT05564390Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Baptist Memorial Hospital and Cancer Center-Collierville, Collierville
- Baptist Memorial Hospital and Cancer Center-Memphis, Memphis
RecruitingPhase 2
Ages 18 to 59 · All sexes · Updated Oct 28, 2026 · NCT05554393A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
- Saint Jude Children's Research Hospital, Memphis
RecruitingPhase 1
Up to age 21 · All sexes · Updated Oct 23, 2026 · NCT07012044Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
- St. Jude Children's Research Hospital, Memphis
RecruitingPhase 1
Ages 1 to 30 · All sexes · Updated Oct 22, 2026 · NCT06177067CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)
- Sarah Cannon Research Insitute, Nashville
RecruitingPhase 1
Ages 18 to 85 · All sexes · Updated Oct 21, 2026 · NCT06834282Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
- Sarah Cannon Center for Blood Cancer at TriStar Centennia, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 16, 2026 · NCT06846606A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Vanderbilt University Medical Center, Nashville
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Oct 6, 2026 · NCT04256317A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Tristar Centennial Medical Center /ID# 275831, Nashville
RecruitingPhase 1
6 Months – 17 Years · All sexes · Updated Oct 5, 2026 · NCT07306832A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- T C Thompson Children's Hospital, Chattanooga
- East Tennessee Childrens Hospital, Knoxville
- The Children's Hospital at TriStar Centennial, Nashville
- and 1 more
RecruitingPhase 3
6 Months – 21 Years · All sexes · Updated Sep 17, 2026 · NCT04293562A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia
- St. Jude Children's Research Hospital, Memphis
RecruitingPhase 2
29 Days – 21 Years · All sexes · Updated Sep 17, 2026 · NCT05955261A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia
- St. Jude Children's Research Hospital, Memphis
RecruitingPhase 1
Up to age 25 · All sexes · Updated Sep 15, 2026 · NCT06810583Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
- East Tennessee Childrens Hospital, Knoxville
- The Children's Hospital at TriStar Centennial, Nashville
RecruitingPhase 3
Ages 1 to 25 · All sexes · Updated Sep 4, 2026 · NCT07022678The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- East Tennessee Childrens Hospital, Knoxville
- Saint Jude Children's Research Hospital, Memphis
- The Children's Hospital at TriStar Centennial, Nashville
- and 1 more
RecruitingPhase 1/2
Up to age 22 · All sexes · Updated Aug 25, 2026 · NCT04726241Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Vanderbilt University Medical Center, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT06001788Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia
- Baptist Health Care Corporation, Memphis
- Vanderbilt University/Ingram Cancer Center, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT06399640Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Vanderbilt University, Ingram Cancer Center, Nashville
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 7, 2026 · NCT07216443A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- St. Jude Childrens Research Hospital, Memphis
- Vanderbilt University, Nashville
RecruitingObservational study
All ages · All sexes · Updated Jul 6, 2026 · NCT01351545Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy
- St. Jude Children's Research Hospital, Memphis
RecruitingPhase 1
Up to age 21 · All sexes · Updated Apr 22, 2026 · NCT05101551A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- TriStar Centennial Medical Center, Nashville
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Mar 24, 2026 · NCT04988555A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
- Sarah Cannon Cancer Institute, Nashville
- Vanderbilt University Medical Center, Nashville
RecruitingPhase 1
Ages 12 and older · All sexes · Updated Mar 16, 2026 · NCT06994676A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- TriStar Bone Marrow Transplant, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Mar 13, 2026 · NCT05735184A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
- Vanderbilt University, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 9, 2026 · NCT06950034CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
- St. Jude Children's Research Hospital, Memphis
RecruitingPhase 1
Up to age 21 · All sexes · Updated Jan 23, 2026 · NCT06326463A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
- Sarah Cannon Research Institute, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 24, 2025 · NCT06501196Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
- TriStar Bone Marrow Transplant, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 15, 2024 · NCT06034275From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.